Chinese Traditional and Herbal Drugs
|
2025, 56(2): 529-535
Exploring tumour-suppressive effect and mechanism of action of Zilongjin Tablets combined with icotinib in Lewis tumor-bearing mice based on EGFR/PI3K/Akt signalling pathway
Full
LI Zhen, JIANG Kun, ZHANG Hongliang, LI Qi, YANG Baijing
Affiliations
doi: 10.7501/j.issn.0253-2670.2025.02.016
Outline
Objective To investigate the mechanism of tumour-suppressive effect and apoptosis of Zilongjin Tablets combined with icotinib through epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway in tumor-bearing mice.Methods Lewis lung cancer mouse model was established, and ten mice were randomly divided into model group, Zilongjin Tablets (375 mg/kg) group, icotinib (5 mg/kg) group, and Zilongjin Tablets (375 mg/kg) + icotinib (5 mg/kg) combination treatment group, with ten mice in each group. Each administration group ig the corresponding drug (10 mL/kg), and the model group ig an equal amount of saline, twice/d, at an interval of 12 h for 14 d. The transplanted tumor was resected after the last administration of the drug, and the tumor mass and tumor volume were observed, and the tumor growth inhibition rate was calculated, the hematoxylin-eosin (HE) staining was used to observe the pathological and morphological changes of the tumors in mice, terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) method was used to determine the apoptosis rate of the tumor cells. Western blotting (WB) was used to detect Bcl-2-associated X protein (Bax), B-cell lymphoma-2 (Bcl-2), cystein-asparate protease-9 (Caspase-9), and EGFR/PI3K/Akt pathway related protein expression. Results Compared with the model group, the transplanted tumor mass and tumor growth inhibition rate of mice in the Zilongjin Tablets group, the icotinib group and the combined treatment group were significantly reduced (P < 0.05), compared with the drug alone, the tumor growth inhibition rate of the combined treatment group was significantly reduced (P < 0.05). HE results showed that necrosis of varying degrees was observed in tumor tissues of the various groups of the drug administration, with the most pronounced necrotic areas in the combined treatment group. TUNEL assay results showed that the apoptosis rate of tumor cells in each administration group was significantly higher compared with that in the model group (P < 0.05, 0.01, 0.001), and the apoptosis rate of tumor cells in the combination therapy group was significantly higher compared with that in the drug alone administration group (P < 0.05, 0.01). WB results showed that the expression of Bax and Caspase-9 was significantly higher in tumor tissues of the Zuolongjin Tablets group, the icotinib group and the combination therapy group compared with that in the model group (P < 0.05, 0.01, 0.001), and Bcl-2 expression was significantly lower (P < 0.05, 0.01, 0.001), the most obvious changes were observed in the combination therapy group compared with the drug alone administration group (P < 0.05), compared with the administration of the drug alone, the combined treatment group showed the greatest decrease (P < 0.05). Conclusion Zilongjin Tablets combined with icotinib can significantly inhibit the growth of tumors and promote apoptosis of tumor cells in tumor-bearing mice, and the mechanism may be to synergistically exert a tumor-suppressive effect by regulating the key targets of the EGFR/PI3K/Akt signalling pathway, up-regulating the expression of pro-apoptotic proteins Bax and Caspase-9, and down-regulating the expression of anti-apoptotic protein Bcl-2.
EGFR/PI3K/Akt signalling pathway
/
Zilongjin Tablets
/
icotinib
/
Lewis tumor-bearing mice
/
antitumor
李朕, 姜坤, 张洪亮, 李琦, 杨百京.
基于EGFR/PI3K/Akt信号通路探讨紫龙金片联合埃克替尼对Lewis荷瘤小鼠的抑瘤作用及机制.
中草药,
2025
, 56
(2)
: 529
-535
.
DOI: 10.7501/j.issn.0253-2670.2025.02.016
LI Zhen, JIANG Kun, ZHANG Hongliang, LI Qi, YANG Baijing.
Exploring tumour-suppressive effect and mechanism of action of Zilongjin Tablets combined with icotinib in Lewis tumor-bearing mice based on EGFR/PI3K/Akt signalling pathway[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(2)
: 529
-535
.
DOI: 10.7501/j.issn.0253-2670.2025.02.016
Year 2025 volume 56 Issue 2
39
8
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.02.016
- Receive Date:2024-08-20
- Online Date:2026-11-13